Haizhu Chen

507 total citations
45 papers, 281 citations indexed

About

Haizhu Chen is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Haizhu Chen has authored 45 papers receiving a total of 281 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 20 papers in Pathology and Forensic Medicine and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Haizhu Chen's work include Lymphoma Diagnosis and Treatment (20 papers), Lung Cancer Treatments and Mutations (10 papers) and Viral-associated cancers and disorders (9 papers). Haizhu Chen is often cited by papers focused on Lymphoma Diagnosis and Treatment (20 papers), Lung Cancer Treatments and Mutations (10 papers) and Viral-associated cancers and disorders (9 papers). Haizhu Chen collaborates with scholars based in China, United States and Macao. Haizhu Chen's co-authors include Yunxia Tao, Yu Zhou, Yuankai Shi, Yuankai Shi, Qiaofeng Zhong, Le Tang, Xiaohong Han, Herui Yao, Daquan Wang and Yu Feng and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Haizhu Chen

42 papers receiving 279 citations

Peers

Haizhu Chen
Lina Inagaki Japan
Philipp Berning Germany
Jennifer Kherani United States
Crystal Hilger United States
Jakob Madsen Denmark
Ali Abdulnabi Suwaidan United Kingdom
Loïck Galland France
Cristina Morelli Italy
Yueyun Chen China
Alireza Rezvani Iran
Lina Inagaki Japan
Haizhu Chen
Citations per year, relative to Haizhu Chen Haizhu Chen (= 1×) peers Lina Inagaki

Countries citing papers authored by Haizhu Chen

Since Specialization
Citations

This map shows the geographic impact of Haizhu Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haizhu Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haizhu Chen more than expected).

Fields of papers citing papers by Haizhu Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haizhu Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haizhu Chen. The network helps show where Haizhu Chen may publish in the future.

Co-authorship network of co-authors of Haizhu Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Haizhu Chen. A scholar is included among the top collaborators of Haizhu Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haizhu Chen. Haizhu Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Huang, Zhenjun, Qing Peng, Luhui Mao, et al.. (2025). Neoadjuvant Strategies for Triple Negative Breast Cancer: Current Evidence and Future Perspectives. SHILAP Revista de lepidopterología. 4(1). 4 indexed citations
4.
Yu, Yunfang, Haizhu Chen, Wenhao Ouyang, et al.. (2024). Unraveling the role of M1 macrophage and CXCL9 in predicting immune checkpoint inhibitor efficacy through multicohort analysis and single‐cell RNA sequencing. SHILAP Revista de lepidopterología. 5(3). e471–e471. 10 indexed citations
5.
Chen, Xinrui, Yan Qin, Xuemin Xue, et al.. (2024). Multi-omics analysis and response prediction of PD-1 monoclonal antibody containing regimens in patients with relapsed/refractory diffuse large B-cell lymphoma. Cancer Immunology Immunotherapy. 73(12). 250–250. 2 indexed citations
6.
Tao, Yunxia, et al.. (2024). Real‑world evaluation of the efficacy of immune checkpoint inhibitors in the treatment of metastatic breast cancer. Oncology Letters. 29(1). 29–29. 5 indexed citations
7.
8.
Feng, Yu, Yunxia Tao, Haizhu Chen, et al.. (2023). Efficacy and safety of immune checkpoint inhibitor rechallenge in non‐small cell lung cancer: A systematic review and meta‐analysis. Thoracic Cancer. 14(25). 2536–2547. 15 indexed citations
9.
10.
Chen, Haizhu, Xingbin Hu, Daquan Wang, et al.. (2023). Association of PIK3CA mutation with outcomes in HER2-positive breast cancer treated with anti-HER2 therapy: A meta-analysis and bioinformatic analysis of TCGA‑BRCA data. Translational Oncology. 37. 101738–101738. 8 indexed citations
11.
12.
Lin, Ling, Daquan Wang, & Haizhu Chen. (2023). The characteristics and survival of second primary lung cancer after Hodgkin’s lymphoma: A comparison with first primary lung cancer using the SEER database. PLoS ONE. 18(5). e0285766–e0285766. 1 indexed citations
13.
Tao, Yunxia, Yu Zhou, Le Tang, et al.. (2022). Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis. Investigational New Drugs. 40(4). 831–840. 11 indexed citations
14.
Shi, Yuankai, Haizhu Chen, Yan Qin, et al.. (2022). Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab (2005–2018). SHILAP Revista de lepidopterología. 1(1). 3–11. 4 indexed citations
15.
Zhong, Qiaofeng, Yunxia Tao, Haizhu Chen, et al.. (2021). The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020. The Lancet Regional Health - Western Pacific. 11. 100151–100151. 19 indexed citations
16.
17.
Chen, Chen, et al.. (2021). Trends of Phase I Clinical Trials of New Drugs in Mainland China Over the Past 10 Years (2011–2020). Frontiers in Medicine. 8. 777698–777698. 9 indexed citations
18.
Chen, Haizhu, Yan Qin, Jianliang Yang, et al.. (2020). Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma. Annals of Hematology. 99(12). 2847–2857. 3 indexed citations
19.
Chen, Haizhu, Daquan Wang, Qiaofeng Zhong, et al.. (2020). Pretreatment body mass index and clinical outcomes in cancer patients following immune checkpoint inhibitors: a systematic review and meta-analysis. Cancer Immunology Immunotherapy. 69(12). 2413–2424. 21 indexed citations
20.
Chen, Haizhu, et al.. (2019). Serum Homocysteine and Vitamin B12 as Biomarkers for Haematological Toxicity in Lung Adenocarcinoma Treated With Pemetrexed. SHILAP Revista de lepidopterología. 30(1). 107–113. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lina Inagaki Breakdown of academic impact, for papers by Philipp Berning Breakdown of academic impact, for papers by Jennifer Kherani Breakdown of academic impact, for papers by Crystal Hilger Breakdown of academic impact, for papers by Jakob Madsen Breakdown of academic impact, for papers by Ali Abdulnabi Suwaidan Breakdown of academic impact, for papers by Loïck Galland Breakdown of academic impact, for papers by Cristina Morelli Breakdown of academic impact, for papers by Yueyun Chen Breakdown of academic impact, for papers by Alireza Rezvani
Rankless by CCL
2026